Change in COVID-19 risk over time following vaccination with CoronaVac : A testnegative case-control study
OBJECTIVE: To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil.
DESIGN: Test negative case-control study.
SETTING: Community testing for covid-19 in São Paulo state, Brazil.
PARTICIPANTS: Adults aged 18-120 years who were residents of São Paulo state, without a previous laboratory-confirmed covid-19 infection, who received only two doses of CoronaVac, and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 30 September 2021.
MAIN OUTCOME MEASURES: RT-PCR-confirmed symptomatic covid-19 and associated hospital admissions and deaths. Cases were pair-matched to test-negative controls by age (in 5-year bands), municipality of residence, healthcare worker (HCW) status, and date of RT-PCR test (±3 days). Conditional logistic regression was adjusted for sex, number of covid-19-associated comorbidities, race, and previous acute respiratory infection.
RESULTS: From 137,820 eligible individuals, 37,929 cases with symptomatic covid-19 and 25,756 test-negative controls with covid-19 symptoms were formed into 37,929 matched pairs. Adjusted odds ratios of symptomatic covid-19 increased with time since series completion, and this increase was greater in younger individuals, and among HCWs compared to non-HCWs. Adjusted odds ratios of covid-19 hospitalisation or death were significantly increased from 98 days since series completion, compared to individuals vaccinated 14-41 days previously: 1.40 (95% confidence interval 1.09 to 1.79) from 98-125 days, 1.55 (1.16 to 2.07) from 126-153 days, 1.56 (1.12 to 2.18) from 154-181 days, and 2.12 (1.39-3.22) from 182 days.
CONCLUSIONS: In the general population of São Paulo state, Brazil, an increase in odds of moderate and severe covid-19 outcomes was observed over time following primary series completion with CoronaVac.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2021 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2021) vom: 24. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hitchings, Matt D T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Brazil |
|---|
| Anmerkungen: |
Date Revised 05.11.2023 published: Electronic UpdateIn: BMJ. 2022 Jun 13;377:e070102. - PMID 35697361 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2021.12.23.21268335 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335239250 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335239250 | ||
| 003 | DE-627 | ||
| 005 | 20231225225404.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.12.23.21268335 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM335239250 | ||
| 035 | |a (NLM)34988559 | ||
| 035 | |a (PII)2021.12.23.21268335 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hitchings, Matt D T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Change in COVID-19 risk over time following vaccination with CoronaVac |b A testnegative case-control study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: BMJ. 2022 Jun 13;377:e070102. - PMID 35697361 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a OBJECTIVE: To estimate the change in odds of covid-19 over time following primary series completion of the inactivated whole virus vaccine, CoronaVac (Sinovac Biotech) in São Paulo state, Brazil | ||
| 520 | |a DESIGN: Test negative case-control study | ||
| 520 | |a SETTING: Community testing for covid-19 in São Paulo state, Brazil | ||
| 520 | |a PARTICIPANTS: Adults aged 18-120 years who were residents of São Paulo state, without a previous laboratory-confirmed covid-19 infection, who received only two doses of CoronaVac, and underwent reverse transcription polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 from 17 January to 30 September 2021 | ||
| 520 | |a MAIN OUTCOME MEASURES: RT-PCR-confirmed symptomatic covid-19 and associated hospital admissions and deaths. Cases were pair-matched to test-negative controls by age (in 5-year bands), municipality of residence, healthcare worker (HCW) status, and date of RT-PCR test (±3 days). Conditional logistic regression was adjusted for sex, number of covid-19-associated comorbidities, race, and previous acute respiratory infection | ||
| 520 | |a RESULTS: From 137,820 eligible individuals, 37,929 cases with symptomatic covid-19 and 25,756 test-negative controls with covid-19 symptoms were formed into 37,929 matched pairs. Adjusted odds ratios of symptomatic covid-19 increased with time since series completion, and this increase was greater in younger individuals, and among HCWs compared to non-HCWs. Adjusted odds ratios of covid-19 hospitalisation or death were significantly increased from 98 days since series completion, compared to individuals vaccinated 14-41 days previously: 1.40 (95% confidence interval 1.09 to 1.79) from 98-125 days, 1.55 (1.16 to 2.07) from 126-153 days, 1.56 (1.12 to 2.18) from 154-181 days, and 2.12 (1.39-3.22) from 182 days | ||
| 520 | |a CONCLUSIONS: In the general population of São Paulo state, Brazil, an increase in odds of moderate and severe covid-19 outcomes was observed over time following primary series completion with CoronaVac | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a Brazil | |
| 650 | 4 | |a CoronaVac | |
| 650 | 4 | |a case-control study | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a inactivated vaccine | |
| 650 | 4 | |a test-negative study | |
| 650 | 4 | |a vaccine | |
| 650 | 4 | |a waning | |
| 700 | 1 | |a Ranzani, Otavio T |e verfasserin |4 aut | |
| 700 | 1 | |a Lind, Margaret L |e verfasserin |4 aut | |
| 700 | 1 | |a Dorion, Murilo |e verfasserin |4 aut | |
| 700 | 1 | |a D'Agostini, Tatiana Lang |e verfasserin |4 aut | |
| 700 | 1 | |a de Paula, Regiane Cardoso |e verfasserin |4 aut | |
| 700 | 1 | |a de Paula, Olivia Ferreira Pereira |e verfasserin |4 aut | |
| 700 | 1 | |a de Moura Villela, Edlaine Faria |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Mario Sergio Scaramuzzini |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira, Silvano Barbosa |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz, Wade |e verfasserin |4 aut | |
| 700 | 1 | |a Almiron, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Said, Rodrigo |e verfasserin |4 aut | |
| 700 | 1 | |a de Oliveira, Roberto Dias |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva, Patricia Vieira |e verfasserin |4 aut | |
| 700 | 1 | |a de Araújo, Wildo Navegantes |e verfasserin |4 aut | |
| 700 | 1 | |a Gorinchteyn, Jean Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Dean, Natalie E |e verfasserin |4 aut | |
| 700 | 1 | |a Andrews, Jason R |e verfasserin |4 aut | |
| 700 | 1 | |a Cummings, Derek A T |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Albert I |e verfasserin |4 aut | |
| 700 | 1 | |a Croda, Julio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2021) vom: 24. Dez. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2021 |g day:24 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.12.23.21268335 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 24 |c 12 | ||